Vitronectin-driven human keratinocyte locomotion is mediated by the alpha v beta 5 integrin receptor.
Vitronectin is a soluble serum factor that is known to promote epiboly of keratinocytes in explant cultures and enhance cell spreading and attachment to matrix. Recently, vitronectin was demonstrated to promote human keratinocyte locomotion. The mechanism(s) by which vitronectin enhances keratinocyte migration is unknown. In this study, we quantitated the vitronectin-driven migration of human keratinocytes in the presence of antibodies to vitronectin receptors. We found that vitronectin's effect of promoting human keratinocyte migration was inhibited by antibody-directed against the alpha v beta 5 receptor. In addition, we surface-labeled human keratinocytes, chromatographed extracts of the cell membranes on a vitronectin column, and then immunoprecipitated the bound and eluted proteins with antibodies to specific vitronectin receptors. We identified the vitronectin receptors on human keratinocytes as bands of 150,000 and 100,000 daltons without reduction and as 125,000 and 110,000 daltons under reducing conditions. Immunoprecipitation with specific antibodies identified the major receptor to be the alpha v beta 5 integrin. In addition, we quantitated vitronectin-driven migration of human keratinocytes in the presence of Arg-Gly-Asp (RGD) and control peptides. We found that the presence of RGD, but not control peptide, inhibited vitronectin-driven migration of human keratinocytes. These studies demonstrate that human keratinocytes express vitronectin receptors and use the alpha v beta 5 receptor for cellular locomotion.
Kim
J P
JP
Department of Dermatology, Stanford University School of Medicine, California 94305.
Zhang
K
K
Chen
J D
JD
Kramer
R H
RH
Woodley
D T
DT
D000906:Antibodies / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006023:Glycoproteins / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D039641:Integrin beta Chains; D039661:Integrin beta3; D016023:Integrins / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D015603:Keratinocytes / Q000187:drug effects / Q000502:physiology*; D009842:Oligopeptides / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D016024:Receptors, Cytoadhesin / Q000276:immunology / Q000378:metabolism*; D019030:Receptors, Vitronectin; D019096:Vitronectin
D000906:Antibodies; D006023:Glycoproteins; D039641:Integrin beta Chains; D039661:Integrin beta3; D016023:Integrins; D009842:Oligopeptides; D016024:Receptors, Cytoadhesin; D019030:Receptors, Vitronectin; D019096:Vitronectin; C064660:integrin alphaVbeta5; C084344:integrin beta5; C047981:arginyl-glycyl-aspartic acid